Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosialoganglioside for Albumin-bound Paclitaxel-induced Neurotoxicity
NCT04538833Phase 2Withdrawn
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in taxane-induced peripheral neuropathy (TIPN) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Functional Assessment of Cancer Therapy-Neurotoxicity. Planned start Sep 2020; status: withdrawn.
02
Conditions
taxane-induced peripheral neuropathy (TIPN)
Beyond the preview
Go deeper on NCT04538833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538833.